Biocon could file as many as five biosimilars in the US and EU in FY 2017


It is gearing up to be a big next few years for biosimilars. Biocon is expected to file as many as five biosimilars in the United States and Europe during fiscal year 2017. Biocon’s biopharma sector has not done as well recently, and management attributed the slow 4 percent growth of the sector to API and capacity constraints. Still, Biocon is using investments and acquisitions to shore this up, and the company believes that biosimilar use in the coming years will drive growth.

Read the source article at biopharma-reporter.com

About the Author

Related Posts

Leave a Reply